PD-1 inhibitor versus bevacizumab in combination with platinum-based chemotherapy for first-line treatment of advanced lung adenocarcinoma: A retrospective-real world study

BACKGROUND: Chemotherapy combined with immunotherapy or anti-vascular therapy is both recommended by guidelines for first-line treatment of lung adenocarcinoma. However, no head-to-head clinical trial has ever compared which strategy is the optimal choice. This real-world retrospective study was don...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Zhe, Zhou, Chunhua, Xiong, Yi, Yang, Feng, Zeng, Fanxu, Jiang, Wenjuan, Zhang, Yongchang, Yang, Haiyan, Liu, Li, Zeng, Liang, Yang, Nong, Wang, Zhan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683483/
https://www.ncbi.nlm.nih.gov/pubmed/36439441
http://dx.doi.org/10.3389/fonc.2022.909721